ANTX - CIK 0001880438
The table below shows AN2 Therapeutics, Inc.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$29.83M | -$49.26M | -$53.29M | -$33.46M | -$20.48M |
| Capital expenditure | - | - | - | - | - |
| Investing cash flow | $28.31M | $54.59M | -$43.28M | -$21.77M | -$50.02M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
AN2 Therapeutics, Inc. reported operating cash flow of -$29.83M for fiscal year 2025. That is up 39.4% from -$49.26M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$20.48M (FY 2021) to -$29.83M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $113.00K | $372.00K | $84.99M | $70.36M | $78.53M |